Latafix

Timolol maleate and Latanoprost, the active ingredients in Latafix, are a beta‑blocker and a prostaglandin analog presented as eye drops for ocular use. They are indicated for the reduction of intra‑ocular pressure in patients with glaucoma or ocular hypertension. GNH USA supplies Latafix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latafix is an antiglaucoma combination that lowers intra‑ocular pressure in several ocular conditions. - Open‑angle glaucoma: reduces eye pressure to prevent optic nerve damage. - Ocular hypertension: lowers intra‑ocular pressure to reduce the risk of progression to glaucoma. - Secondary glaucoma (e.g., steroid‑induced): helps control pressure when other agents are insufficient.

Latafix may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye irritation: mild burning or stinging on instillation. - Blurred vision: temporary visual disturbance after dosing. - Eye redness: conjunctival hyperemia. - Dry eye: reduced tear production. - Headache: mild, transient.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or anaphylaxis. - Significant reduction in heart rate: bradycardia. - Exacerbation of asthma: bronchospasm. - Iridocyclitis: intra‑ocular inflammation.

Before prescribing Latafix, consider the following safety measures. - Contraindicated in patients with known hypersensitivity to timolol, latanoprost or any component of the formulation. - Use with caution in patients with asthma or chronic obstructive pulmonary disease. - Monitor heart rate and blood pressure in patients with cardiac disease. - Avoid concurrent use with other beta‑blocker eye drops. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at room temperature: keep in original container, protect from light and moisture.

Latafix can interact with systemic and ocular medications.

Major Interactions (Avoid): - Systemic beta‑blockers: additive bradycardia and hypotension. - Non‑selective beta‑blocker inhalers: increased risk of bronchospasm. - MAO inhibitors: potential for severe hypertension.

Moderate Interactions (Monitor Closely): - Other prostaglandin analogues: additive ocular effects. - Topical ocular anesthetics: may increase corneal toxicity. - Anticholinergic agents: may affect pupil response.